B

iotech stocks in 2017 were a lot like toddlers: Lovely, affectionate, and playful, but also cranky, volatile, aggravating.

Big picture: The Nasdaq Biotechnology Index performed essentially in line with the broader markets — not great but certainly not a disaster, especially for a turbulent year during which health care investors seemed to be on constant edge about the next Trump tweet.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.